Skip to main content
All lobbying filings

EDWARDS LIFESCIENCES, LLC

Lobbying for EDWARDS LIFESCIENCES LLC

 Filing 1st Quarter - Report
1st Quarter (Jan 1 - Mar 31) 2025 · California · House · Senate · $350,000.00 expenses · posted Apr 18, 2025

Official filing document

 Bills named in this filing 2
  • S 5349
    Ensuring Patient Access to Critical Breakthrough Products Act of 2024
  • HR 1691
    Ensuring Patient Access to Critical Breakthrough Products Act of 2024
 Lobbying activity 5
Health Issues

Ensuring Patient Access to Critical Breakthrough Products (H.R.1691 S.5349) Transitional Coverage for Emerging Technologies (TCET) Guidance Policies promoting medical innovation Heart Valve Disease Awareness FDA Reauthorization for 2022/FDA User Fees Diversity in Clinical Trials Coverage with Evidence Development

Medicare/Medicaid

CMS Coverage Policies for Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.1691/S.5349) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Diversity in Clinical Trials Coverage with Evidence Development

Taxation/Internal Revenue Code

Corporate Tax Reform Proposals

Trade (domestic/foreign)

Tariffs

Veterans

Veterans Access to MedTech

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem